REVIEW
Does the GH–IGF axis play a role in cancer pathogenesis?

https://doi.org/10.1054/ghir.2000.0171Get rights and content

Abstract

Recent case-controlled studies have found increases in the serum levels of insulin-like growth factor-I (IGF-I) in subjects who had, or who eventually developed, prostate or premenopausal breast cancers. Since growth hormone (GH) increases IGF-I levels, concern has been raised regarding its potential role as a cancer initiation factor. The epidemiological studies, which indicate an association between serum IGF-I levels and cancer risk, have not established causality. In fact, several alternative explanations for the elevated serum IGF-I levels in cancer patients may be proposed based on human and animal models. First, an effect of IGF-I causing symptomatic benign tissue hyperplasia may result in an ascertainment bias leading to an initiation of procedures resulting in the diagnosis of asymptomatic cancers. Second, elevated serum IGF-I in cancer patients may originate within the tumor (as suggested by some animal studies). Thirdly, serum IGF-I may actually be a surrogate marker of tissue IGF-I levels or of nutritional factors, which are not under GH control and may be involved in cancer initiation. The role of GH in cancer initiation is further negated by the fact that in acromegaly, the incidence of cancer, other than possibly colonic neoplasia does not appear to be significantly increased. Furthermore, GH transgenic mice, with high IGF-I levels, do not develop breast, prostate, or colonic malignancies. It is known that IGFBP-3 can inhibit IGF action on cancer cells in vitro and also can induce apoptosis via an IGF-independent mechanism. Importantly, in addition to increasing IGF-I levels, GH also increases the serum levels of IGFBP-3 and serum IGFBP-3 levels have been shown to be negatively correlated with the risk of cancer in the above mentioned epidemiological studies and in a similar study on colon cancer. These studies suggest that cancer risk is increased in individuals in whom both high IGF-I levels and low IGFBP-3 levels are present. In subjects treated with GH, IGF-I and IGFBP-3 levels both rise together and are not within the elevated cancer-risk range, based on published studies. Long-term studies are needed to assess the potential risks, including the long-term cancer risk associated with GH therapy. These should take into account several factors, including the duration of exposure, the risk magnitude associated with the degree of serum IGF-I elevation, and the adjusted risk based on a concomitant increase in IGFBP-3 levels. Since GH treated patients often have sub-normal IGF-I serum levels, which normalize on therapy, one might predict that their cancer risk on GH therapy should not increase above the normal population. Until further research in the area dictates otherwise, on-going cancer surveillance and routine monitoring of serum IGF-I and IGFBP-3 levels in GH-recipients should be the standard of care. At present, the data that are available do not warrant a change in our current management of approved indications for GH therapy.

References (90)

  • C.S. Mantzoros et al.

    Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia

    Br J Cancer

    (1997)
  • H. Yu et al.

    Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis

    J Natl Cancer Inst

    (1999)
  • J.M. Chan et al.

    Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

    Science

    (1998)
  • T.A. Serel et al.

    Serum insulin-like growth factor is not a useful marker of prostate cancer

    BJU Int

    (2000)
  • R. Kurek et al.

    The significance of serum levels of insulin-like growth factor-1 in patients with prostate cancer

    BJU Int

    (2000)
  • H. Jernstrom et al.

    Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo Study

    J Women’s Health Gend Based Med

    (1999)
  • E. Petridou et al.

    Insulin-like growth factor-I and binding protein-3 in relation to childhood leukaemia

    Int J Cancer

    (1999)
  • J. Ma et al.

    Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3

    J Natl Cancer Inst

    (1999)
  • E. Ron et al.

    Acromegaly and gastrointestinal cancer

    Cancer

    (1991)
  • V. Popovic et al.

    Increased incidence of neoplasia in patients with pituitary adenomas. The Pituitary Study Group

    Clin Endocrinol (Oxf)

    (1998)
  • B.A. Bengtsson et al.

    Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984

    Acta Med Scand

    (1988)
  • B. Delhougne et al.

    The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients

    J Clin Endocrinol Metab

    (1995)
  • S.D. Ladas et al.

    Does acromegaly really predispose to an increased prevalence of gastrointestinal tumours?

    Clin Endocrinol (Oxf)

    (1994)
  • S.M. Orme et al.

    Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group

    J Clin Endocrinol Metab

    (1998)
  • P.H. Sonksen et al.

    Acromegaly and colonic cancer

    Clin Endocrinol

    (1997)
  • A.G. Renehan et al.

    Colorectal neoplasia in acromegaly: the reported increased prevalence is overestimated

    Gut

    (2000)
  • P. Maison et al.

    Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study

    BMJ

    (1998)
  • A. Colao et al.

    Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly

    Clin Endocrinol (Oxf)

    (1997)
  • A. Colao et al.

    Prostatic hyperplasia: an unknown feature of acromegaly

    J Clin Endocrinol Metab

    (1998)
  • S.T. Ng et al.

    Growth hormone treatment induces mammary gland hyperplasia in aging primates

    Nat Med

    (1997)
  • A.J. Butt et al.

    The IGF axis and programmed cell death

    Immunol Cell Biol

    (1999)
  • A. Grimberg et al.

    Role of IGFs in growth control and carcinogenesis

    J Cell Physiol

    (2000)
  • D. LeRoith et al.

    Insulin-like growth factors in pediatric health and disease

    J Clin Endocrinol Metab

    (1999)
  • P. Angelloz-Nicoud et al.

    Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3)

    Endocrinol

    (1995)
  • J.A. Figueroa et al.

    Proliferation of cultured human prostate cancer cells is inhibited by insulin- like growth factor (IGF) binding protein-I: evidence for an IGF- II autocrine growth loop

    J Clin Endocrinol Metab

    (1995)
  • S.R. Plymate et al.

    The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen

    J Clin Endocrinol Metab

    (1996)
  • M.K. Tennant et al.

    Protein and messenger ribonucleic acid (mRNA) for the type I insulin-like growth factor (IGF) receptor is decreased and IGFII mRNA is increased in human prostate carcinoma compared to benign prostate epithelium

    J Clin Endocrinol Metab

    (1996)
  • Y.Z. Wang et al.

    Sex hormone-induced prostatic carcinogenesis in the Noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer

    Prostate

    (1998)
  • R. Rajah et al.

    IGFBP proteases – functional regulators of cell growth

    Progress in Growth Factors Research

    (1996)
  • P. Cohen et al.

    The IGF axis in the prostate

    Horm Metab Res

    (1994)
  • S.E. Nunn et al.

    Regulation of prostate cell growth by the insulin-like growth factor binding proteins and their proteases

    Endocrine

    (1997)
  • P. Cohen et al.

    Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma

    J Clin Endocrinol Metab

    (1992)
  • P. Cohen et al.

    Biological effects of prostate specific antigen (PSA) as an IGFBP-3 protease

    J Endocrinol

    (1994)
  • S.E. Nunn et al.

    Acid-activated insulin-like growth factor binding protein protease activity of cathepsin D in normal and malignant prostatic epithelial cells and seminal plasma

    J Cell Physiol

    (1997)
  • Cited by (149)

    • Physiologic Growth Hormone–Replacement Therapy and Craniopharyngioma Recurrence in Pediatric Patients: A Meta-Analysis

      2018, World Neurosurgery
      Citation Excerpt :

      Both growth hormone and IGF-1 have well-established mitogenic and antiapoptotic properties.25-27 Therefore, these agents have previously been proposed to play a considerable role in carcinogenesis and tumor growth, with several groups demonstrating an association between serum IGF-1 levels and prostate, breast, and colon cancer risks.28-30 In addition, the increased risk of developing certain malignancies as a result of elevated growth hormone are consistent with observations in patients with acromegaly who have elevated levels of circulating growth hormone and IGF-1.

    • Insulin-like growth factor binding-protein-3 (IGFBP-3)

      2015, Best Practice and Research: Clinical Endocrinology and Metabolism
    • Increased genome instability and oxidative DNA damage and their association with IGF-1 levels in patients with active acromegaly

      2014, Growth Hormone and IGF Research
      Citation Excerpt :

      It is reported that acromegaly patients have an increased risk of developing both benign and malignant tumours, particularly colorectal cancer, and possibly other cancers such as breast, prostate, thyroid and haematological malignancies [7,8]. The aetiology of these cancers remains uncertain, but they may be related to both growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels [9–14]. However, some epidemiological studies report conflicting findings on cancer risk in acromegaly [15,16].

    • GH and IGF1 in cancer therapy resistance

      2023, Endocrine-Related Cancer
    View all citing articles on Scopus
    View full text